Neurodegenerative diseases: Reactive oxygen species and programmed cell death;Maladies neurodegeneratives: Role des especes activees de l'oxygene et de l'apoptose

Presse Medicale

Volumn 28, Issue 30, 1999, Pages 1661-1666

  Follezou J Y ^a,b   Emerit, J ^b   Bricaire, F ^b  

^a Centre des Tumeurs   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; EXCITOTOXIN; GLUTAMIC ACID; REACTIVE OXYGEN METABOLITE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NERVE CELL DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; METABOLISM; MOUSE;

AIDS DEMENTIA COMPLEX; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEURODEGENERATIVE DISEASES; REACTIVE OXYGEN SPECIES;

EID: 0033539220     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Yun HY, Dawson VL, Dawson TM. Neurobiology of Nitric Oxide. Critical Reviews in Neurobiology 1996 ; 10:291-316.
2. Halliwell B, Gutteridge JMC. Oxygen radicals and the nervous system. Trends Neurosci 1985 ; 8:22-6.
3. Cohen JJ. Apoptosis. Immunol Today 1993 ; 14:126-30.
4. Siddique T, Figlewicz MA, Paricak MA et al. Linkage of a gene causing FALS to chromosome 21. N Engl J Med 1991 ; 324:1380-4.
5. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu-Zn SOD gene are associated with FALS Nature 1993 ; 362:59-62.
6. Sapp P, Rosen D, Hosler B et al. Identification of 3 novel mutations in the gene for Cu-Zn SOD in patients with FALS. Neuromusc Disord 1995 ; 5:353-7.
7. Gumey ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice expressing a human Cu-Zn SOD mutation. Science 1994 ; 264:1172-5.
8. Bowling AC, Barkoxski EE, Mackenna-Yasek D et al. SOD concentration and activity in FALS. J Neurochem 1995 ; 64:2366-9.
9. Robberecht W, Sapp P, Viaene MK. Cu-Zn SOD Activity in FALS and in sporadic ALS. J Neurochem 1994 ; 62:384-7.
10. Brown RH JR. SOD in FALS: models for gain of function. Current Opinion in Neurobiology 1995 ; 5:841-6.
11. Wiedau-Pazos M, Goto JJ, Ravidazadeh S et al. Altered reactivity of SOD in FALS. Science 1996 ; 271:515-18.
12. Beckman JS, Carson M, Smith CD, Koppenol W. H. ALS, SOD and peroxynitrite. Nature 1993 ; 364:584.
13. Ravizadeh S, Gralla EB, Borchelt DR et al. Mutations associated with ALS convert SOD from an antiapoptic gene to a proapoptic gene. Proc Natl Acod Sci USA 1995 ; 92:3024-8.
14. o/peroxynitrite pathway. J Neurosci 1996 ; 16:253-61.
15. Gurney ME, Cuttings FB, Zai P et al. Benefit of vitamine E, riluzole, and gabapentin in a transgenic model of FALS. Ann Neurol 1996 ; 39:147-57.
16. Wong PC, Pardo CA, Borchelt DR et al. An adverse property of a FALS linked SOD mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995 ; 14:1105-16.
17. Shibata N, Hirano A, Kobayashi A et al. Cu-Zn SOD like immuno reactivity in Lewy body-like indusions of sporadic ALS. Neurosci Lett 1994 ; 179:149-52.
18. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994 ; 15:7-10.
19. Rothstein JD, Bristol LA, Hoosler B et al. Chronic inhibition of SOD produces apoptic death of spinal neurons. Proc Natl Acad Sci USA 1994 ; 91:4155-9.
20. Grimm, Bauer MKA, Bauerle PA et al. Bcl-2 down-regulates the activity of NF-kB induced upon apoptisis. J Cell Biol 1988 ; 134:13-23.
21. Coyl JT, Puttfarcken P, Coyl JT, Puttfarcken P. Oxidative stress glutamate and neurodegenerative disorders. Science 1993 ; 262:689-95.
22. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 ; 330:613-22.
23. Levine RL. Oxidative modification of glutamine-synthase. J Biol Chem 1983 ; 258:11826-7.
24. Carney JM, Starke Reed PE, Olivier CW et al. Reversal of age related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spartial memory by chronic administration of spin trapping compound N-tertbutyl-a-phenylnitrone. Proc Natl Acad Sci USA 1991 ; 88:3633-6.
25. Choi DW. ALS and glutamate - Too much of a good thing. N Engl J Med 1992 ; 326:1493-5.
26. o and related nitroso-compounds. Nature 1993 ; 364:626-32.
27. Mecocci P, Macgarvey U, Kaufman AE et al. Oxidative damage to mithochondrial DNA shows marked age dependent increases in human brain. Ann Neurol 1993 ; 34:609-16.
28. Beal MF. Does impairment of energy metabolism results in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992 ; 31:119-30.
29. Adamson DC, Wilddemann B, Sasaki M et al. Immunologic NOS: Elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996 ; 274:1917-21.
30. Olanow CW. An introduction to the free radical hypothesis in Parkinson's Disease. Ann Neurol 1992 ; 32:S2-9.
31. Choi BH. Oxidative stress and Alzheimer's disease. Neurobiol Aging 1995 ; 16:675-8.
32. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995 ; 38:557-68.
33. Lipton SA, Gendelman HE. Dementia associated with AIDS. N Engl J Med 1995 ; 332:934-40.
34. Bukrinsky MI, Nottet HS, Schmidtmayeriva H et al. Regulation of nitric oxide synthase activity in HIV-1 infected monocytes: implications for HIV-associated neurological disease. J Exp Med 1995 ; 181:735-45.
35. o in primary cortical culture. Proc Natl Acad Sci USA 1993 ; 90:3256-60.
36. Olanow CW. A radical hypothesis for neurodegeneration. TINS 1993 ; 16:439-44.
37. Dexter D, Carter C, Javoy H et al. Basal lipid peroxidation is increased in Parkinson's disease. J Neuroche 1989 ; 52:53692-7.
38. Ben-Sachar D, Riedeerer P, Youdim MBH. Iron melanin interaction and lipid peroidation: implications for Parkinson's Disease. J Neurochem 1991 ; 57:609-12.
39. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease. Brain Res 1992 ; 5933:343-6.
40. Gutteridge JMC. Iron and oxygen radicals in brain. Ann Neurol 1992 ; 32:S16-22.
41. Jenner P, Dexter DT, Sian J et al. Oxidative stress as a cause of nigral cell death in Parkinson's Disease and incidental Lewy body disease. Ann Neurol 1992 ; 32:S82-8.
42. o in MPTP induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996 ; 93:3456-60.
43. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997 ; 23:134-47.
44. Smith MA, Perry G, Richey PL et al. Oxidative damage in Alzheimer's disease. Nature 1996 ; 382:120-2.
45. Hensley K, Carney JM, Mattson MP et al. A model of ß-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer's disease. Proc Natl Acad Sci USA 1994 ; 91:3270-4.
46. Harris ME, Carney JM, Cole PS et al. ß-amyloid derived OFR inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Neuroreport 1995 ; 6:1875-9.
47. Mark RJ, Lovell MA, Markesbery WR et al. A role of 4-hydroxynonenal, in disruption of ion homeostasis and neuronal death induced by ß-amyloid-peptide. J Neurochem 1997 ; 8:255-64.
48. Mark RJ, Blance M, Mattson MT. Amytoid-ß-peptide and oxidativecellular injury in Alzheimer's disease. Mol Neurobiol 1996 ; 38:211-24.
49. Smith CD, Carney JM, Starke-Reed PE et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer's disease. Proc Natl Acad Sci USA 1991 ; 88:10540-3.
50. Carpenter AF, Carpenter PW, Markesbery WR Morphometric analysis of microglia in Alzheimer's disease. J Neuropathol Exp Neur 1993 ; 52:601-8.
51. Smith MA, Sayre LM, Monnier VM, Perry G. Radical Ageing in Alzheimer's disease. Trends Neurosciences 1995 ; 18:172-6.
52. Sano M, Emesto C, Thmasr G et al. A controlled trial of Selegine, alpha-tocopherol or both as treament for Alzheimer's disease. N Engl J Med 1997 ; 336:1216-22.
53. Crappermaclachlan DR, Dalton AJ, Kruck TPA et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991 ; 337:1304-8.
54. Reiter RJ. Antioxidant action of melatonin. Adv Pharmacol 1997 ; 38:103-11.
55. Mattson MP, Lovell MA, Furukawa K, Markesbery WR. Neurotrophic factors attenuate glutamate induced accumulation of peroxides, elevation of intracellular calcium concentration, and neurotoxicity and increase antioxidant enzyme activities in hippoccampal neurons. J Neurochem 1995 ; 65:1740-51.